CDKN2A and ovarian cancer: Head and neck squamous cell carcinoma has a loss rate of CDKN2A that may exceed 80%, and esophageal cancer, ovarian cancer, and pancreatic cancer all show evidence of homozygous loss of CDKN2A [18].